Grifols starts two Phase 3 trials to expand immunoglobulin labels

July 16, 2026 8:01 AM

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced that the first patients have been dosed in two separate Phase 3 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found